Table 1.
Summary of mouse cohortsa
| Cohort | Crosses | Age (mo) | Outcomes | Figure | Female 'n' |
Male 'n' |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WT | Tc1/Dpx | AppNL-F/NL-F | Tc1/Dpx; AppNL-F/NL-F | WT | Tc1/Dpx | AppNL-F/NL-F | Tc1/Dpx; AppNL-F/NL-F | |||||
| 1 | Tc1;AppNL-F/+ and AppNL-F/+ | 3 | APP and APP-CTF abundance | 3 | 4 | 3 | 2 | 4 | 4 | 5 | 2 | 4 |
| 2 | Dp(10)2Yey;AppNL-F/+ and AppNL-F/+ | 3 | APP and APP-CTF abundance | 8 | 1 | 0 | 0 | 2 | 4 | 8 | 9 | 4 |
| 3 | Dp3Tyb-AppNL-F/+ and AppNL-F/+ Dp3Tyb and C57BL/6J AppNL-F/+ and AppNL-F/+ | 3 | APP, APP-CTF, DYRK1A, and BACE2 abundance | 7, 10, 11 | 6 | 5 | 8 | 5 | 11 | 7 | 7 | 8 |
| Human Aβ fragments (only AppNL-F carriers analyzed) | ||||||||||||
| 4 | Dp3Tyb and C57BL/6J | 3 | Mouse Aβ abundance | 9 | 5 | 7 | NA | NA | 11 | 12 | NA | NA |
| 5 | Tc1;AppNL-F/+ and AppNL-F/+ | 8 | 82E1 plaque counts | 2 | 5 | 5 | 15 | 8 | 0 | 3 | 8 | 10 |
| Human Aβ abundance | ||||||||||||
| 6 | Dp3Tyb-AppNL-F/+ and AppNL-F/+ AppNL-F/+ and AppNL-F/+ | 8 | 82E1 plaque counts | 4–6 | 2 | NA because of breed scheme | 2 | 9 | 2 | NA because of breed scheme | 7 | 5 |
| Human Aβ abundance | ||||||||||||
| 7 | Dp(10)2Yey;AppNL-F/+ and AppNL-F/+ | 8 | 82E1 plaque counts | 4–6 | 2 | 2 | 4 | 6 | 4 | 1 | 5 | 3 |
| Human Aβ abundance | ||||||||||||
| 8 | Dp(17)3Yey;AppNL-F/+ and AppNL-F/+ | 8 | 82E1 plaque counts | 4–6 | 3 | 3 | 7 | 7 | 3 | 3 | 5 | 7 |
| Human Aβ abundance | ||||||||||||
aSummary of the cohorts of mice, the cross(es) used to generate them, the age at which the cohort was killed, the outcome measured, and the figure in which the data are presented.